{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:34:46Z","timestamp":1784244886797,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma GmbH Austria"},{"name":"Institute for Advanced Studies Vienna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease leading to reduced (healthy) life years. The aim of this study is to quantify the societal costs associated with hypercholesterolemia. We use epidemiologic data on the distribution of cholesterol levels as well as data on relative risks regarding ischemic heart disease, stroke, and other cardiovascular diseases. The analytical approach is based on the use of population-attributable fractions applied to direct medical, direct non-medical and indirect costs using data of Austria. Within a life-cycle analysis we sum up the costs of hypercholesterolemia for the population of 2019 and, thus, consider future morbidity and mortality effects on this population. Epidemiologic data suggest that approximately half of Austria\u2019s population have low-density lipoprotein cholesterol (LDL-C) levels above the target levels (i.e., are exposed to increased risk). We estimate that 8.2% of deaths are attributable to hypercholesterolemia. Total costs amount to about 0.33% of GDP in the single-period view. In the life-cycle perspective, total costs amount to \u20ac806.06 million, \u20ac312.1 million of which are medical costs, and about \u20ac494 million arise due to production loss associated with hypercholesterolemia. The study points out that significant shares of deaths, entries into disability pension and care allowance, full-time equivalents lost to the labor market as well as monetary costs for the health system and the society could be avoided if LDL-C-levels of the population were reduced.<\/jats:p>","DOI":"10.1007\/s10198-024-01684-0","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:02:42Z","timestamp":1711105362000},"page":"1595-1603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Costs attributable to hypercholesterolemia in a single period and over the life cycle"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-1794","authenticated-orcid":false,"given":"Stephanie","family":"Reitzinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-7341","authenticated-orcid":false,"given":"Miriam","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-1075","authenticated-orcid":false,"given":"Thomas","family":"Czypionka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/heartjnl-2020-317549","volume":"107","author":"D De Bacquer","year":"2021","unstructured":"De Bacquer, D., van de Luitgaarden, I.A.T., De Smedt, D., Vynckier, P., Bruthans, J., Fras, Z., Jankowski, P., Dolzhenko, M., Kotseva, K., Wood, D., De Backer, G.: Socioeconomic characteristics of patients with coronary heart disease in relation to their cardiovascular risk profile. Heart 107, 799\u2013806 (2021). https:\/\/doi.org\/10.1136\/heartjnl-2020-317549","journal-title":"Heart"},{"key":"1684_CR2","doi-asserted-by":"publisher","first-page":"e001236","DOI":"10.1161\/JAHA.114.001236","volume":"3","author":"L Mundal","year":"2014","unstructured":"Mundal, L., Sarancic, M., Ose, L., Iversen, P.O., Borgan, J., Veier\u00f8d, M.B., Leren, T.P., Retterst\u00f8l, K.: Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992\u20132010. J. Am. Heart Assoc. 3, e001236 (2014). https:\/\/doi.org\/10.1161\/JAHA.114.001236","journal-title":"J. Am. Heart Assoc."},{"key":"1684_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo, A., Casula, M., Olmastroni, E., Norata, G.D., Catapano, A.L.: Global epidemiology of dyslipidaemias. Nat. Rev. Cardiol.Cardiol. 18, 689\u2013700 (2021). https:\/\/doi.org\/10.1038\/s41569-021-00541-4","journal-title":"Nat. Rev. Cardiol.Cardiol."},{"key":"1684_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","volume":"582","author":"NCD Risk Factor Collaboration","year":"2020","unstructured":"NCD Risk Factor Collaboration: Repositioning of the global epicentre of non-optimal cholesterol. Nature 582, 73\u201377 (2020). https:\/\/doi.org\/10.1038\/s41586-020-2338-1","journal-title":"Nature"},{"key":"1684_CR5","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jval.2017.05.014","volume":"20","author":"W-H Cheng","year":"2017","unstructured":"Cheng, W.-H., Gaudette, \u00c9., Goldman, D.P.: PCSK9 inhibitors show value for patients and the US health care system. Value Health 20, 1270\u20131278 (2017). https:\/\/doi.org\/10.1016\/j.jval.2017.05.014","journal-title":"Value Health"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"A339","DOI":"10.1016\/j.jval.2014.08.668","volume":"17","author":"M Gouveia","year":"2014","unstructured":"Gouveia, M., Borges, M., Augusto, M., Caldeira, D., Alarc\u00e3o, J., Pinheiro, L., Sousa, R., Fareleira, F., Ascen\u00e7\u00e3o, R., Costa, J., Laires, P., Fiuza, M., Dias, N.C., Martins, S., Belo, A., Vaz-Carneiro, A.: Cost and burden of hypercholesterolemia in Portugal. Value Health 17, A339 (2014). https:\/\/doi.org\/10.1016\/j.jval.2014.08.668","journal-title":"Value Health"},{"key":"1684_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00392-007-0602-0","volume":"97","author":"J M\u00fcller-Nordhorn","year":"2008","unstructured":"M\u00fcller-Nordhorn, J., Englert, H., Wegscheider, K., Berger, H., Sonntag, F., V\u00f6ller, H., Meyer-Sabellek, W., Reinhold, T., Windler, E., Katus, H.A., Willich, S.N.: Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany. Clin. Res. Cardiol.Cardiol. 97, 152\u2013159 (2008). https:\/\/doi.org\/10.1007\/s00392-007-0602-0","journal-title":"Clin. Res. Cardiol.Cardiol."},{"key":"1684_CR8","doi-asserted-by":"publisher","DOI":"10.3386\/w11405","volume-title":"The Value of Health and Longevity","author":"K Murphy","year":"2005","unstructured":"Murphy, K., Topel, R.: The Value of Health and Longevity. National Bureau of Economic Research, Cambridge, MA (2005)"},{"key":"1684_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00508-011-0057-1","volume":"123","author":"H Drexel","year":"2011","unstructured":"Drexel, H., Chazelle, F., Fauer, C., Lautsch, D., Gitt, A.K.: Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events\u2013\u2013results of the dyslipidemia international study (DYSIS). Wien. Klin. Wochenschr.Wochenschr. 123, 611\u2013617 (2011). https:\/\/doi.org\/10.1007\/s00508-011-0057-1","journal-title":"Wien. Klin. Wochenschr.Wochenschr."},{"key":"1684_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., Chapman, M.J., De Backer, G.G., Delgado, V., Ference, B.A., Graham, I.M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T.R., Riccardi, G., Richter, D.J., Sabatine, M.S., Taskinen, M.R., Tokgozoglu, L., Wiklund, O., Mueller, C., Drexel, H., Aboyans, V., Corsini, A., Doehner, W., Farnier, M., Gigante, B., Kayikcioglu, M., Krstacic, G., Lambrinou, E., Lewis, B.S., Masip, J., Moulin, P., Petersen, S., Petronio, A.S., Piepoli, M.F., Pint\u00f3, X., R\u00e4ber, L., Ray, K.K., Reiner, \u017d, Riesen, W.F., Roffi, M., Schmid, J.P., Shlyakhto, E., Simpson, I.A., Stroes, E., Sudano, I., Tselepis, A.D., Viigimaa, M., Vindis, C., Vonbank, A., Vrablik, M., Vrsalovic, M., Zamorano, J.L., Collet, J.P., Koskinas, K.C., Casula, M., Badimon, L., John Chapman, M., De Backer, G.G., Delgado, V., Ference, B.A., Graham, I.M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T.R., Riccardi, G., Richter, D.J., Sabatine, M.S., Taskinen, M.R., Tokgozoglu, L., Wiklund, O., Windecker, S., Aboyans, V., Baigent, C., Collet, J.P., Dean, V., Delgado, V., Fitzsimons, D., Gale, C.P., Grobbee, D., Halvorsen, S., Hindricks, G., Iung, B., J\u00fcni, P., Katus, H.A., Landmesser, U., Leclercq, C., Lettino, M., Lewis, B.S., Merkely, B., Mueller, C., Petersen, S., Petronio, A.S., Richter, D.J., Roffi, M., Shlyakhto, E., Simpson, I.A., Sousa Uva, M., Touyz, R.M., Nibouche, D., Zelveian, P.H., Siostrzonek, P., Najafov, R., van de Borne, P., Pojskic, B., Postadzhiyan, A., Kypris, L., \u0160pinar, J., Larsen, M.L., Eldin, H.S., Viigimaa, M., Strandberg, T.E., Ferri\u00e8res, J., Agladze, R., Laufs, U., Rallidis, L., Bajnok, L., Gudj\u00f3nsson, T., Maher, V., Henkin, Y., Gulizia, M.M., Mussagaliyeva, A., Bajraktari, G., Kerimkulova, A., Latkovskis, G., Hamoui, O., Slapikas, R., Visser, L., Dingli, P., Ivanov, V., Boskovic, A., Nazzi, M., Visseren, F., Mitevska, I., Retterst\u00f8l, K., Jankowski, P., Fontes-Carvalho, R., Gaita, D., Ezhov, M., Foscoli, M., Giga, V., Pella, D., Fras, Z., de Isla, L.P., Hagstr\u00f6m, E., Lehmann, R., Abid, L., Ozdogan, O., Mitchenko, O., Patel, R.S.: ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk ESC Scientific Document Group. Eur. Heart J. 41, 111\u2013188 (2020)","journal-title":"Eur. Heart J."},{"key":"1684_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00103-013-1670-0","volume":"56","author":"C Scheidt-Nave","year":"2013","unstructured":"Scheidt-Nave, C., Du, Y., Knopf, H., Schienkiewitz, A., Ziese, T., Nowossadeck, E., G\u00f6\u00dfwald, A., Busch, M.A.: Verbreitung von fettstoffwechselst\u00f6rungen bei erwachsenen in deutschland: ergebnisse der studie zur gesundheit erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 56, 661\u2013667 (2013). https:\/\/doi.org\/10.1007\/s00103-013-1670-0","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"1684_CR12","unstructured":"NCD Risk Factor Collaboration: https:\/\/www.ncdrisc.org\/cholesterol-tc-ranking.html. Accessed 15 Sep 2023"},{"key":"1684_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12944-022-01721-y","volume":"21","author":"Z Li","year":"2022","unstructured":"Li, Z., Zhu, G., Chen, G., Luo, M., Liu, X., Chen, Z., Qian, J.: Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007\u20132018. Lipids Health Dis. 21, 111 (2022). https:\/\/doi.org\/10.1186\/s12944-022-01721-y","journal-title":"Lipids Health Dis."},{"key":"1684_CR14","volume-title":"Konsistente Sch\u00e4tzung von Pr\u00e4valenz","author":"U Frick","year":"2011","unstructured":"Frick, U., Rehm, J.: Konsistente Sch\u00e4tzung von Pr\u00e4valenz. Koronare Herzkrankheiten Hauptverband, Inzidenz und krankheitsspezifischer Mortalit\u00e4t f\u00fcr \u00d6sterreich (2011)"},{"key":"1684_CR15","unstructured":"\u00d6GSF: Zahlen und Fakten, https:\/\/www.ogsf.at\/stroke-units\/zahlen-und-fakten\/. Accessed 13 Sep 2023"},{"key":"1684_CR16","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.3399\/bjgp19X702725","volume":"69","author":"J Buddeke","year":"2019","unstructured":"Buddeke, J., Bots, M.L., van Dis, I., Visseren, F.L., Hollander, M., Schellevis, F.G., Vaartjes, I.: Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data. Br. J. Gen. Pract.Pract. 69, e398\u2013e406 (2019). https:\/\/doi.org\/10.3399\/bjgp19X702725","journal-title":"Br. J. Gen. Pract.Pract."},{"key":"1684_CR17","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1055\/s-0042-123977","volume":"142","author":"F-W Dippel","year":"2017","unstructured":"Dippel, F.-W., Parhofer, K., M\u00fcller-Bohn, T., Gebhardt, S., Kostev, K.: Sekund\u00e4rdatenanalyse zur ermittlung der pr\u00e4valenz von kardiovaskul\u00e4ren hochrisiko-patienten mit hypercholesterin\u00e4mie und therapierefrakt\u00e4rem behandlungsverlauf. DMW \u2013 Dtsch. Med. Wochenschr. 142, e34\u2013e41 (2017). https:\/\/doi.org\/10.1055\/s-0042-123977","journal-title":"DMW \u2013 Dtsch. Med. Wochenschr."},{"key":"1684_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047","volume-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","author":"KK Ray","year":"2020","unstructured":"Ray, K.K., et al.: EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur. J. Prev. Cardiol. (2020). https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047"},{"key":"1684_CR19","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti, S.O., Madsen, C.M., Varbo, A., Nordestgaard, B.G.: Worldwide prevalence of familial hypercholesterolemia. J. Am. Coll. Cardiol.Cardiol. 75, 2553\u20132566 (2020). https:\/\/doi.org\/10.1016\/j.jacc.2020.03.057","journal-title":"J. Am. Coll. Cardiol.Cardiol."},{"key":"1684_CR20","unstructured":"Statistik Austria: Austrian Health Interview Survey (ATHIS), https:\/\/www.statistik.at\/fileadmin\/publications\/Oesterreichische-Gesundheitsbefragung2019_Hauptergebnisse.pdf (2019), Accessed 25 May 2022"},{"key":"1684_CR21","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"Prospective Studies Collaboration","year":"2007","unstructured":"Prospective Studies Collaboration: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 370, 1829\u20131839 (2007). https:\/\/doi.org\/10.1016\/S0140-6736(07)61778-4","journal-title":"Lancet"},{"key":"1684_CR22","unstructured":"DESTATIS: Cost of illness, https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Health\/Cost-Illness\/_node.html (2015), Accessed 29 Aug 2022"},{"key":"1684_CR23","unstructured":"Dachverband: Jahresbericht der \u00f6sterreichischen Sozial. 2019, https:\/\/www.sozialversicherung.at\/cdscontent\/load?contentid=10008.684097&version=1561377321. Accessed 29 July 2022"},{"key":"1684_CR24","unstructured":"PRIKRAF: Jahresbericht 2019, https:\/\/www.prikraf.info\/images\/downloads\/JB2019.pdf (2019), Accessed 25 May 2022"},{"key":"1684_CR25","unstructured":"Statistik Austria: Health Expenditure, https:\/\/statistik.at\/statistiken\/bevoelkerung-und-soziales\/gesundheit\/gesundheitsversorgung-und-ausgaben\/gesundheitsausgaben (2019), Accessed 06 Sept 2022"},{"key":"1684_CR26","volume-title":"Demography: Measuring and Modeling Population Processes","author":"SH Preston","year":"2001","unstructured":"Preston, S.H., Heuveline, P., Guillot, M.: Demography: Measuring and Modeling Population Processes. Blackwell Publishers, Malden, MA (2001)"},{"key":"1684_CR27","unstructured":"Statistik Ausria: Cause of death statistics, https:\/\/statcube.at\/statistik.at\/ext\/statcube\/jsf\/tableView\/tableView.xhtml. Accessed 18 Sep 2023"},{"key":"1684_CR28","unstructured":"Statistik Austria: STATcube\u2013Statistische Datenbank., http:\/\/www.statistik.at\/web_de\/services\/statcube\/index.html (2019), Accessed 15 Aug 2022"},{"key":"1684_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jval.2015.06.002","volume":"18","author":"PK Rannanheimo","year":"2015","unstructured":"Rannanheimo, P.K., Tiittanen, P., Hartikainen, J., Helin-Salmivaara, A., Huupponen, R., Vahtera, J., Korhonen, M.J.: Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland. Value Health 18, 896\u2013905 (2015). https:\/\/doi.org\/10.1016\/j.jval.2015.06.002","journal-title":"Value Health"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01684-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-024-01684-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01684-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T16:03:09Z","timestamp":1729958589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-024-01684-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s10198-024-01684-0","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a grant from Novartis Pharma GmbH Austria. SR, MR and TC have no conflict of interests and certify that they have no other affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}